Compare LQDA & CALM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | CALM |
|---|---|---|
| Founded | 2004 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2020 | 1996 |
| Metric | LQDA | CALM |
|---|---|---|
| Price | $63.23 | $74.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $41.00 | ★ $92.00 |
| AVG Volume (30 Days) | ★ 1.7M | 675.0K |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | 51.81 | ★ 338.49 |
| EPS | 0.52 | ★ 7.34 |
| Revenue | $158,320,000.00 | ★ $1,351,609,000.00 |
| Revenue This Year | $278.87 | N/A |
| Revenue Next Year | $57.13 | N/A |
| P/E Ratio | $107.10 | ★ $10.27 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $71.92 |
| 52 Week High | $63.46 | $126.40 |
| Indicator | LQDA | CALM |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 42.60 |
| Support Level | $30.48 | $72.83 |
| Resistance Level | $63.46 | $79.75 |
| Average True Range (ATR) | 3.55 | 2.00 |
| MACD | -0.68 | -0.19 |
| Stochastic Oscillator | 74.24 | 16.16 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.